The Phase 2 data provide a foundation for registrational trial design. Key catalysts to watch: disclosure of pivotal trial design by 1H 2027, data update at a medical meeting in mid-2027, and Phase 1b breast cancer data in 2H 2027.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $12.68entry
- T+1 · 7d ago +1.89%α +2.26% · $12.92
- T+5 · 15h ago −26.81%α −25.12% · $9.28
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer, showing a 33% confirmed ORR and preliminary median PFS of 7.4 months in a heavily pre-treated population. The safety profile appears differentiated with low rates of hyperglycemia and stomatitis. The company plans to disclose a registrational trial design by 1H 2027.
Key Facts
- Confirmed ORR of 33% (12/36) in efficacy-evaluable patients; DCR of 83%
- Preliminary median PFS of 7.4 months (95% CI 5.3, NR) in all 42 treated patients
- Preliminary 6-month PFS rate of 62% (95% CI 43, 75)
- Confirmed ORR of 44% and DCR of 81% among patients with PIK3CA mutation
- 2 of 42 patients (5%) discontinued due to treatment-related adverse events
- All-grade hyperglycemia 12% (2% grade 3); all-grade stomatitis 21% (2% grade 3)
- 16 of 42 patients remain on treatment; median duration of response not reached
- Pivotal trial design expected by 1H 2027, subject to regulatory alignment
Financial Impact
U.S. TAM for 2L endometrioid endometrial cancer estimated at ~$2.5B; PIKTOR's price not yet set
Risk Factors
- Single-arm Phase 2 study with small sample size (n=42); results may change with additional follow-up
- Cross-trial comparisons only; no head-to-head trials conducted
- PIKTOR is investigational and not yet approved by any regulatory authority
- Regulatory alignment on pivotal trial design is not guaranteed
- Company's ability to obtain additional capital to fund development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452755 |
| Document: d19560d8k.htm | 0001193125-26-452755 |
| Document: 0001193125-26-452755-index-headers.html | 0001193125-26-452755 |
| Document: 0001193125-26-452755-index.html | 0001193125-26-452755 |
| Document: 0001193125-26-452755.txt | 0001193125-26-452755 |
Track record
12 reports on FTH
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $9.28 −7.48% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $19.65 to $19.99 Now $9.28 −52.77% ▲ +1.73% +0.08% vs SPY
- Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $9.28 −51.67% ▼ −2.34% −1.96% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $9.28 −51.44% ▲ +0.47% +0.13% vs SPY
- Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $9.28 −72.90% ▲ +2.60% +1.47% vs SPY
- Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $9.28 +69.07% ▲ +2.07% +2.32% vs SPY
- Aug 4, 202614w ago 8-K Neutral 3/10 Entry $25.50 to $24.59 Now $9.28 −63.61% ▼ −3.57% −3.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers